Shares of Lupin rose from the day's lows on Friday, July 30, after the company received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) and commercially launched Sugammadex Injection in the United States. According to reports from CNBC TV18 and Business Standard, the company has launched Sugammadex Injection in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial presentations. The launch follows approval of the company's ANDA by the USFDA, as reported in an exchange filing on Friday, with the company transitioning from tentative regulatory clearance received in March 2026 to active commercialization in the United States. As per latest reports, the drug addresses a significant need in anesthesiology where precise control over neuromuscular blockade is essential, with Sugammadex being critical for patient safety by enabling faster emergence from anesthesia and reduced time in recovery rooms.
As reported by CNBC TV18 and Business Standard, Lupin's product is bioequivalent to Merck's Bridion Injection and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged two years and older undergoing surgery. Sugammadex is used to reverse the effects of certain muscle relaxants administered during surgical procedures, helping patients recover muscle function after anaesthesia. The commercial launch strengthens Lupin's high-margin complex injectables segment, reducing reliance on competitive oral solids and providing stable, recurring institutional revenues in the high-barrier sterile injectables market. By launching this generic version, Lupin aims to provide hospitals and surgical centers with a therapeutic equivalent that reduces costs compared to the branded option, with the company introducing the drug in two specific strengths, packaged as single-dose vials with a consistent concentration of 100 mg/mL.
In a significant development, Lupin has also received approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Diazepam Injection USP, 10 mg/2 mL single-dose prefilled syringes. According to CNBC TV18, the USFDA approved Lupin's product as bioequivalent to the reference listed drug (RLD) Valium Injection 10 mg/2 mL (5 mg/mL) of Hoffmann-La Roche Inc. The product is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. According to IQVIA MAT May 2026 data, Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), single-dose prefilled syringes had estimated annual sales of $77.9 million in the United States, representing a substantial market opportunity for Lupin's generic version.
The launch underscores Lupin's strategic focus on differentiating its pipeline beyond commodity generics, as complex generics like neuromuscular blockers and anti-anxiety medications require rigorous bioequivalence studies and specialized manufacturing capabilities. As reported by latest sources, the addition of Sugammadex and Diazepam to Lupin's U.S. portfolio complements its existing presence in multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin operates as a global pharmaceutical leader with products distributed in over 100 markets, supporting its operations with 15 state-of-the-art manufacturing sites and 7 research centers globally, employing over 26,000 professionals. The launch aligns with Lupin's broader ecosystem, which includes subsidiaries such as Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, by expanding its foothold in the U.S. market with high-value complex generics to drive sustainable growth and improve patient health outcomes worldwide.
The launch comes at a strategically important time as Lupin prepares for potential tariff impacts on generic pharmaceuticals. According to reports from The Wall Street Journal, President Trump announced plans to impose tariffs on imported generic pharmaceuticals starting in August 2028, with rates rising to 100% initially and 200% a year later after a two-year transition period. This tariff structure is designed to encourage drugmakers to move manufacturing to the United States. By establishing a strong U.S. presence through complex generics like Sugammadex and Diazepam, Lupin is positioning itself to potentially avoid or minimize the impact of these tariffs while maintaining its competitive position in the American market.
According to CNBC TV18, shares of the company gained following the USFDA approval and were trading at ₹2,418.30, down by ₹0.80, or 0.033% on the BSE on Friday. The stock has gained more than 15% so far in 2026, and about 26% over the last 12 months. The commercial launch of Sugammadex Injection represents a key tactical milestone in protecting Lupin's high-performing North American segment, with the company effectively diversifying its U.S. pipeline through higher-margin sterile injectables that provide structural defense against price erosion in oral generic segments. The launch reinforces Lupin's ability to drive complex generic adoption in hospital and clinical settings across the U.S., supporting stable operating margins as the company schedules its Q1 FY27 earnings release for August 6, 2026. While Lupin has not disclosed the expected revenue contribution from the products, continued approvals in this segment could support future earnings and strengthen its presence in the U.S. healthcare market.
